Idorsia’s (SIX: IDIA) shares were down more than 9% at 8.76 Swiss francs by early afternoon, as the Switzerland-based biotech announced its financial results for the first quarter of 2023.
Net revenue for the quarter came in at 21 million francs ($23.6 million), a more than four-fold increase on the 5 million francs posted in the like 2022 period.
US generally accepted accounting principles (GAAP) net loss in the first quarter of 2023 amounted to 212 million francs (198 million francs in the first quarter of 2022). The increase of the net loss was mainly driven by higher operating expenses, largely in the commercial functions, a negative financial result and partially offset by higher net revenues.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze